I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Zevra Therapeutics with a $35 price target, citing strong Q2 performance, accelerating MIPLYFFA adoption, and robust financials. The analyst highlighted significant U.S. market potential for NPC treatment, supported by patent protection until 2041 and updated guidelines. Additionally, Roth MKM maintained a Buy rating with a $21 target.
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Zevra Therapeutics, retaining the price target of $35.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors tied to Zevra’s commercial execution and financial strength. He points to robust second-quarter performance, with revenue and profitability exceeding expectations, driven largely by accelerating MIPLYFFA adoption and a strong gross margin profile supported by a sizable cash position.
He also emphasizes the significant remaining U.S. opportunity as diagnosis rates improve, backed by strategic initiatives, extended patent protection to 2041, and updated treatment guidelines that reinforce MIPLYFFA’s role in NPC care. While acknowledging the EMA’s initial negative opinion, he highlights that Europe is not the core value driver, and he sees additional upside from the progressing DiSCOVER Phase 3 trial in vEDS, which could provide a further catalyst if successful.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $21.00 price target.